Stock 603590 BEIJING KONRUNS PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Beijing Konruns Pharmaceutical Co.,Ltd.

Equities

603590

CNE1000036K3

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
28.2 CNY -1.23% Intraday chart for Beijing Konruns Pharmaceutical Co.,Ltd. -6.53% -25.95%
Apr. 25 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 08 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. Stock Beijing Konruns Pharmaceutical Co.,Ltd.
-25.95% 627M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.73% 728B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 603B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.57% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.81% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.19% 279B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 244B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 207B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 205B
A+
AMGEN INC. Stock Amgen Inc.
+6.49% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 603590 Stock
  4. Ratings Beijing Konruns Pharmaceutical Co.,Ltd.